Tenaya Therapeutics Inc [TNYA] stock prices are up 2.64% to $5.84 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TNYA shares have gain 11.45% over the last week, with a monthly amount glided 39.38%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Tenaya Therapeutics to Participate in Upcoming March Investor Conferences. In a post published today on Yahoo Finance, Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen’s 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows:.
From an analyst’s perspective:
Tenaya Therapeutics Inc [NASDAQ: TNYA] stock has seen the most recent analyst activity on November 30, 2023, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $7. Previously, H.C. Wainwright started tracking the stock with Buy rating on June 15, 2022, and set its price target to $25.
The stock price of Tenaya Therapeutics Inc [TNYA] has been fluctuating between $1.66 and $8.09 over the past year. Tenaya Therapeutics Inc [NASDAQ: TNYA] shares were valued at $5.84 at the most recent close of the market.
Analyzing the TNYA fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.42 points at the first support level, and at 5.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.07, and for the 2nd resistance point, it is at 6.30.
Tenaya Therapeutics Inc [TNYA] reported earnings per share of -$0.39 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.47/share, meaning a difference of $0.08 and a surprise factor of 17.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.45 per share as compared to estimates of -$0.5 per share, a difference of $0.05 representing a surprise of 10.00%.
Ratios To Look Out For
It’s worth pointing out that Tenaya Therapeutics Inc [NASDAQ:TNYA]’s Current Ratio is 6.55. Also, the Quick Ratio is 6.55, while the Cash Ratio stands at 0.05.
Transactions by insiders
Recent insider trading involved Hoey Timothy, Chief Scientific Officer, that happened on Feb 20 when 6569.0 shares were sold. Chief Medical Officer, Tingley Whittemore completed a deal on Feb 16 to sell 6500.0 shares. Meanwhile, Chief Executive Officer Ali Faraz sold 6358.0 shares on Feb 16.
